Silexion Therapeutics (SLXN) Capital Expenditures (2023 - 2025)

Silexion Therapeutics (SLXN) posted quarterly Capital Expenditures of $2000.0 for Q4 2025, up 100.0% quarter-over-quarter from $1000.0 in Q2 2025.

Silexion Therapeutics (SLXN) Capital Expenditures (2023 - 2025) Analysis & Trends

Silexion Therapeutics' Capital Expenditures history runs 3 years deep, the most recent figure standing at $2000.0 for Q4 2025.

In Q4 2025, Capital Expenditures changed N/A year-over-year to $2000.0; the TTM figure through Mar 2026 stood at $3000.0 (down 86.36% YoY), while the FY2025 annual figure was $9000.0, down 59.09% from the prior year.
Capital Expenditures for Q4 2025 stood at $2000.0, up from $1000.0 in the prior quarter.
The five-year high for Capital Expenditures was $16000.0 in Q3 2024, with the low at $1000.0 in Q2 2025.
The 3-year median for Capital Expenditures is $5000.0 (2023), against an average of $5375.0.
The sharpest annual moves came in 2024 and 2025: Capital Expenditures jumped 166.67% in 2024, then changed 0.0% in 2025.
Silexion Therapeutics' Capital Expenditures stood at $4000.0 in 2023, then jumped by 300.0% to $16000.0 in 2024, then tumbled by 87.5% to $2000.0 in 2025.
Business Quant data shows SLXN's Capital Expenditures at $2000.0 in Q4 2025, $1000.0 in Q2 2025, and $6000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Silexion Therapeutics	266,692.97	-1.96 Mn	-	-

Download Data